Results 81 to 90 of about 68,946 (284)

Therapeutic targeting of chromatin alterations in leukemia and solid tumors

International Journal of Cancer, EarlyView.
Abstract Alterations in chromatin conformation and post‐translational modification of histones have become increasingly recognized as critical drivers of cancer development, progression, and therapy resistance. Recent advances in drug development have led to the establishment of several highly selective small molecule inhibitors, several of which are ...
Florian Perner, Tobias Berg, Daniel Sasca, Sophie‐Luise Mersiowsky, Jayant Y. Gadrey, Johanna Thomas, Michael W. M. Kühn, Michael Lübbert   +7 more
wiley   +1 more source

Hypersensitivity of bcr-abl-positive progenitors to hyperthermia in patients with chronic myeloid leukemia [PDF]

Leukemia, 1997
In this study, we evaluated the effect of hyperthermia on hematopoietic progenitors from six chronic myeloid leukemia (CML) bone marrow (BM) samples at diagnosis and four peripheral blood stem cell (PBSC) samples from CML patients after stem cell mobilisation.
Thijsen, S.F.T., van Oostveen, J.W., Schuurhuis, G.J., Theijsmeijer, A.P., Oudejans, C.B.M., van Wijk, I.J., Langenhuijsen, M.M.A.C., Ossenkoppele, G.J.   +7 more
openaire   +6 more sources

Frequency of p190 and p210 BCR-ABL rearrangements and survival in Brazilian adult patients with acute lymphoblastic leukemia

Revista Brasileira de Hematologia e Hemoterapia, 2014
Objective: This study investigated the occurrence of the p190 and p210 break point clusterregion-Abelson (BCR-ABL) rearrangements in adults with acute lymphoblastic leukemia and possible associations with clinical and laboratory characteristics and ...
Ilana de França Azevedo, Rui Milton Patrício da Silva Júnior, Audrey Violeta Martins de Vasconcelos, Washington Batista das Neves, Fárida Coeli de Barros Correia Melo, Raul Antônio Morais Melo   +5 more
doaj   +1 more source

Differential expression of miR-17∼92 identifies BCL2 as a therapeutic target in BCR-ABL-positive B-lineage acute lymphoblastic leukemia

Leukemia, 2013
Despite advances in allogeneic stem cell transplantation, BCR-ABL-positive acute lymphoblastic leukaemia (ALL) remains a high-risk disease, necessitating the development of novel treatment strategies.
M. Scherr, A. Elder, K. Battmer, D. Barzan, S. Bomken, M. Ricke-Hoch, A. Schro¨der, L. Venturini, H. Blair, J. Vormoor, O. Ottmann, A. Ganser, A. Pich, D. Hilfiker-Kleiner, O. Heidenreich, M. Eder   +15 more
semanticscholar   +1 more source

The Hsp90β Isoform: An Attractive Target for Drug Development

Medicinal Research Reviews, EarlyView.
ABSTRACT The beta isoform of 90 kDa heat shock protein (Hsp90β) plays a critical role in maintaining cellular proteostasis by assisting in the folding and refolding of proteins, which is essential for both normal cellular function and stress response.
Subhabrata Chaudhury, Terin D'Amico, Brian S. J. Blagg   +2 more
wiley   +1 more source

The mechanisms of taxodione-induced apoptosis in BCR-ABL-positive leukemia cells

Folia Pharmacologica Japonica, 2019
Chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) are caused by a fusion protein, BCR-ABL, which induces cellular transformation by activating the signaling molecules, STAT5 and Akt. The specific BCR-ABL inhibitors including imatinib, nilotinib, and dasatinib, are clinically utilized in the treatment with CML and ALL patients ...
Kenji Tago, Yuki Uchihara, Megumi Funakoshi-Tago   +2 more
openaire   +3 more sources

Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway

Molecular Cancer, 2019
Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer.
Xuefei Wang, Jianling Yang, Guijie Guo, Riyue Feng, Ke Chen, Yuan Liao, Lianfeng Zhang, Liping Sun, Shile Huang, Ji-Long Chen   +9 more
doaj   +1 more source

SOCS1 function in BCR-ABL mediated myeloproliferative disease is dependent on the cytokine environment. [PDF]

PLoS ONE, 2017
Treatment with tyrosine kinase inhibitors is the standard of care for Philadelphia chromosome positive leukemias. However the eradication of leukemia initiating cells remains a challenge.
Özlem Demirel, Olivier Balló, Pavankumar N G Reddy, Olesya Vakhrusheva, Jing Zhang, Astrid Eichler, Ramona Fernandes, Susanne Badura, Hubert Serve, Christian Brandts   +9 more
doaj   +1 more source

BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein [PDF]

, 2013
Patients with chronic myeloid leukemia in whom tyrosine kinase inhibitors (TKIs) fail often present mutations in the BCR-ABL catalytic domain. We noticed a lack of substitutions involving 4 amino acids (E286, M318, I360, and D381) that form hydrogen ...
Alessandro Pandini, Chiara Romano, Deininger M., Elena Tirrò, Franca Fraternali, Francesco Di Raimondo, Livia Manzella, Michele Massimino, Nagar B., Paolo G. Vigneri, Pietro Buffa, Shah N. P.   +11 more
core   +1 more source

Nanosensors in Leukemia Management: Pioneering Real‐Time Biomarker Detection for Precision Oncology

Nano Select, EarlyView.
This review highlights pioneering nanosensors designed for real‐time leukemia biomarker detection, integrating advanced nanomaterials such as liposomes, polymeric nanoparticles and quantum dots. It examines electrochemical, optical and magnetic detection mechanisms, the applications across AML, ALL, CML, and CLL subtypes, and clinical translation ...
Hamed Soleimani Samarkhazan, Mohammad Navid Khaksari, Amirhossein Mirzazadeh, Mohammad Siavashi, Niloofar Pilehvari, Mohammad Hossein Mohammadi   +5 more
wiley   +1 more source